

Fluvastatin (Lescol[®] / Lescol XL[®])

No. 76/04

Novartis Pharmaceuticals

Summary of Recommendation

9 February, 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a full submission.

Fluvastatin is accepted for restricted use within NHS Scotland for the secondary prevention of coronary events after percutaneous coronary angioplasty (PCI). Fluvastatin is best placed for the management of patients previously untreated with a statin.

In Scotland a significant number of patients being considered for coronary angioplasty are likely to have been prescribed a statin for secondary prevention indications prior to referral for PCI and in these patients there is no need to change the statin used. Fluvastatin was found to reduce the risk of a major adverse coronary event in patients post PCI. The reduction in risk was greatest in patients with diabetes mellitus and multivessel disease. The economic model, compared fluvastatin to placebo rather than active treatment, and for this comparison it was cost effective.

Professor David H Lawson
Chairman